Compare Stocks → Pentagon contract could send this $2 AI stock soaring (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CYADNASDAQ:CYCNNASDAQ:EPIXNASDAQ:ETONNASDAQ:KTOV Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYADCelyad Oncology$0.60$0.67$0.46▼$3.07$15.91MN/AN/A3,009 shsCYCNCyclerion Therapeutics$2.77-9.2%$3.10$1.75▼$6.75$7.51M1.843,211 shs717 shsEPIXESSA Pharma$6.25-2.3%$8.47$2.56▼$11.67$276.50M1.62136,534 shs41,308 shsETONEton Pharmaceuticals$3.21-2.1%$3.93$2.42▼$5.81$82.47M1.1767,142 shs9,117 shsKTOVPurple Biotech$0.49+8.9%$4.16$2.20▼$14.40$7.71M2.371.18 million shs83,344 shs(Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYADCelyad Oncology0.00%0.00%0.00%0.00%-15.13%CYCNCyclerion Therapeutics-6.73%-12.06%-9.18%-19.71%-52.18%EPIXESSA Pharma0.00%-13.86%-29.13%-27.19%+136.16%ETONEton Pharmaceuticals+0.92%+2.82%-17.17%-26.29%-6.29%KTOVPurple Biotech+7.69%-16.01%-26.99%-18.63%-74.21%top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYADCelyad OncologyN/AN/AN/AN/AN/AN/AN/AN/ACYCNCyclerion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AEPIXESSA Pharma1.9788 of 5 stars3.54.00.00.00.03.30.0ETONEton Pharmaceuticals2.1091 of 5 stars3.55.00.00.00.00.80.0KTOVPurple BiotechN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYADCelyad OncologyN/AN/AN/AN/ACYCNCyclerion TherapeuticsN/AN/AN/AN/AEPIXESSA Pharma3.00Buy$16.50164.00% UpsideETONEton Pharmaceuticals3.00Buy$10.00211.53% UpsideKTOVPurple BiotechN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYADCelyad Oncology$110K144.65N/AN/A$0.20 per share3.00CYCNCyclerion Therapeutics$1.62M4.63N/AN/A$4.62 per share0.60EPIXESSA PharmaN/AN/AN/AN/A$3.30 per shareN/AETONEton Pharmaceuticals$31.64M2.61$0.00 per share1,016.96$0.60 per share5.35KTOVPurple Biotech$1M7.71N/AN/A$5.56 per share0.09Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYADCelyad Oncology-$9.14MN/A0.00∞N/AN/AN/AN/AN/ACYCNCyclerion Therapeutics-$5.26M-$5.51N/A∞N/AN/A-111.79%-74.10%5/9/2024 (Estimated)EPIXESSA Pharma-$26.58M-$0.59N/AN/AN/AN/A-17.41%-17.04%5/14/2024 (Estimated)ETONEton Pharmaceuticals-$940K-$0.03N/A∞N/A-2.96%-6.21%-3.17%5/9/2024 (Estimated)KTOVPurple Biotech-$5.85M-$3.00N/AN/AN/AN/AN/AN/AN/ALatest KTOV, CYCN, EPIX, CYAD, and ETON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/14/2024Q4 2023ETONEton Pharmaceuticals-$0.04-$0.09-$0.05-$0.09$7.70 million$7.31 million 2/13/202412/31/2023EPIXESSA Pharma-$0.17-$0.14+$0.03-$0.14N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYADCelyad OncologyN/AN/AN/AN/AN/ACYCNCyclerion TherapeuticsN/AN/AN/AN/AN/AEPIXESSA PharmaN/AN/AN/AN/AN/AETONEton PharmaceuticalsN/AN/AN/AN/AN/AKTOVPurple BiotechN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYADCelyad OncologyN/AN/AN/ACYCNCyclerion TherapeuticsN/A3.853.85EPIXESSA PharmaN/A40.7440.74ETONEton PharmaceuticalsN/A1.651.60KTOVPurple BiotechN/A2.22N/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYADCelyad OncologyN/ACYCNCyclerion Therapeutics75.62%EPIXESSA Pharma75.12%ETONEton Pharmaceuticals27.86%KTOVPurple Biotech30.72%Insider OwnershipCompanyInsider OwnershipCYADCelyad Oncology0.94%CYCNCyclerion Therapeutics13.10%EPIXESSA Pharma14.70%ETONEton Pharmaceuticals13.16%KTOVPurple Biotech2.98%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCYADCelyad Oncology9526.52 million26.28 millionNot OptionableCYCNCyclerion Therapeutics12.71 million2.36 millionNo DataEPIXESSA Pharma5044.24 million37.74 millionOptionableETONEton Pharmaceuticals3025.69 million22.31 millionOptionableKTOVPurple Biotech915.73 millionN/ANot OptionableKTOV, CYCN, EPIX, CYAD, and ETON HeadlinesSourceHeadlinePromising Pipeline Prospects for Purple Biotech: Buy Rating Affirmed Amidst Anticipated Clinical Advancementsmarkets.businessinsider.com - March 6 at 3:56 PMPurple Biotech: Q3 Earnings Insightsbenzinga.com - November 21 at 9:06 AMPurple Biotech GAAP EPS of -$0.23msn.com - November 21 at 9:06 AMPurple Biotech files to sell 4.65M ADS for holdersmsn.com - October 30 at 6:19 PMAlukovinyl Provides Customised And Innovative Purple Car Wrap Films For Car Owners Worldwidebenzinga.com - August 25 at 6:47 AMPurple Biotech Stock (NASDAQ:PPBT), Earnings Estimates, EPS, and Revenuebenzinga.com - August 24 at 8:36 PMPurple Biotech Reports Second Quarter 2023 Financial Resultsbenzinga.com - August 22 at 1:56 PMPPBT Purple Biotech Ltd.seekingalpha.com - July 19 at 1:35 PMPurple Carrot Discount Codeslatimes.com - July 9 at 4:56 PMPurple Promo Codes 2023reuters.com - June 29 at 12:46 PMPurple Biotech (PPBT) Receives a Buy from H.C. Wainwrightmarkets.businessinsider.com - May 17 at 7:09 AMPurple Biotech CEO Gil Efron takes medical leave, Isaac Israel named acting CEOseekingalpha.com - March 24 at 10:06 AMPurple Biotech sees positive results from cancer studylabiotech.eu - March 19 at 7:49 PMRapidly Growing Purple Brands Announces New Director of Winemakingfinance.yahoo.com - September 9 at 4:41 PM‘Purple Hearts’ Star Sofia Carson and Director Elizabeth Allen Rosenbaum Defend Netflix Film After Backlash: ‘Our Intentions Are Very Pure’finance.yahoo.com - August 12 at 7:23 PMDebut Biotech and DIC team up to make Holy Grail in natural food colors: a stable vibrant redfoodnavigator-usa.com - July 28 at 12:10 PMPurple Biotech Names Efron CEO as Israel Steps Down >PPBTmarketwatch.com - July 14 at 10:01 AMBiotech company says woman received 3D printed ear made from her own cellsyahoo.com - June 2 at 3:47 PMPurple Biotech Reports First Quarter 2022 Financial Resultsfinance.yahoo.com - May 12 at 12:16 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCelyad OncologyNASDAQ:CYADCelyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.Cyclerion TherapeuticsNASDAQ:CYCNCyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.ESSA PharmaNASDAQ:EPIXESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.Eton PharmaceuticalsNASDAQ:ETONEton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.Purple BiotechNASDAQ:KTOVPurple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension in the United States, as well as in China and South Korea. Its oncology pipeline includes NT-219, a small molecule that is advancing as a monotherapy treatment of advanced solid tumors and in combination with cetuximab for the treatment of recurrent or metastatic squamous cell carcinoma of head and neck cancer in a planned phase 1/2 study; and CM-24, a monoclonal antibody blocking CEACAM1 that is being developed as a combination therapy with anti-PD1 checkpoint inhibitors for the treatment of non-small cell lung cancer and pancreatic cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. Purple Biotech Ltd. is headquartered in Tel Aviv, Israel. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.